Malachite Innovations, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VBIO research report →
About the company
Vitality Biopharma, Inc. specializes in creating cannabinoid-based pharmaceuticals, primarily focusing on addressing inflammatory disorders within the United States. Its current pipeline includes tetrahydrocannabinol glycoside, identified as VBX-100, an orally administered cannabinoid prodrug engineered to combat inflammatory bowel disease (IBD) and irritable bowel syndromes (IBS).
- CEO
- Michael R. Cavanaugh CPA,
- IPO
- 2008
- Employees
- 3
- HQ
- Los Angeles, CA, US
Price Chart
- Market Cap
- $2.64M
- P/E
- 4.89
- P/S
- 15.57
- P/B
- 2.98
- EV/EBITDA
- 3.89
- Div Yield
- 0.00%
- Gross Margin
- 25.75%
- Op Margin
- -75.92%
- Net Margin
- 311.28%
- ROE
- 91.35%
- ROIC
- -2.52%
- Revenue
- $0 · 0.00%
- Net Income
- $-880,851 · 79.82%
- EPS
- $-0.02 · 79.86%
- Op Income
- $-2,338,213
- FCF YoY
- 55.30%
- 52W High
- $5.60
- 52W Low
- $0.72
- 50D MA
- $1.00
- 200D MA
- $1.84
- Beta
- 1.83
- Avg Volume
- 312.53K
Get TickerSpark's AI analysis on VBIO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 18, 26 | Wolf Lisa G | other | 92 |
| Jun 18, 26 | Wolf Lisa G | other | 92 |
| May 18, 26 | Handley Michael K | other | 2,206 |
| May 18, 26 | Handley Michael K | other | 2,206 |
| May 1, 26 | Lackey Melinda | other | 45,000 |
| May 1, 26 | Lackey Melinda | other | 0 |
| Jul 29, 21 | LoConti Joseph E. | buy | 1,000 |
| Jul 20, 21 | LoConti Joseph E. | buy | 13,000 |
| Jul 19, 21 | LoConti Joseph E. | buy | 20,000 |
| Jul 19, 21 | LoConti Joseph E. | buy | 67,000 |
Our VBIO coverage
Recent articles, reports, and earnings notes.
No research on VBIO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VBIO report →Similar companies
Peers in the same neighborhood.